Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome
Status:
Recruiting
Trial end date:
2024-02-15
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of iscalimab at two dose levels in
patients with Sjögren's Syndrome, who participated in the TWINSS core study,
CCFZ533B2201(NCT03905525). Additionally, this Extension study will further explore the
pharmacokinetics (PK) and efficacy of iscalimab at two dose level.